Upper-Face Botulinum Toxin: Reading Muscles Before Treating Lines
The upper face is where nearly every injector begins, and for a sound reason: mistakes here are visible, temporary and recoverable. A brow that sits too low or a forehead that has stopped moving is a difficult three months, not a lost outcome. That forgiveness is exactly what makes it the right place to learn judgement.
Three muscles, one system
The upper face is not three separate treatment areas. The frontalis is the only muscle that raises the brow; everything else in the region pulls it down. The glabellar complex draws the brows together and downward, and the orbicularis oculi closes the eye and depresses the lateral brow.
Treating any one of them changes the balance of all of them. Weakening the depressors without addressing the elevator lifts the brow; weakening the elevator without the depressors lowers it. Almost every unwanted upper-face result — the heavy brow, the surprised arch, the forehead that moves in one band and not another — comes from treating a line rather than the system that produced it [1].
Assess movement, not photographs
A static face tells you very little. Ask the patient to frown, raise the brows, close the eyes firmly and smile, and watch which muscles are actually doing the work. Two patients with identical glabellar lines can have quite different patterns of activity, and the treatment that suits one will disappoint the other.
Look specifically for a patient who is already using the frontalis to hold the brows up — often someone with heavy upper lids who is compensating without realising it. Reducing that compensation produces exactly the outcome they feared: eyes that look more hooded, not less. This group is the single most common source of upper-face dissatisfaction, and identifying them is a matter of watching the face at rest for ten seconds.
Where lines are not the problem
Deep, etched lines that remain when the face is completely still have a skin component that a muscle relaxant cannot address. Treating them can soften them over time as the skin is given a rest from repeated folding, but promising resolution sets up failure. Say plainly which lines will soften and which will not.
Similarly, brow position that has changed through descent rather than muscle activity is not a toxin problem. Offering toxin because it is what you have is how patients end up with a treated face and an untouched complaint [3].
The complications worth understanding
Two are worth knowing in detail because both are avoidable and both take weeks to resolve.
Brow ptosis follows over-treatment of the frontalis, particularly low on the forehead, and is more likely in patients who were compensating. It reads as heaviness rather than smoothness, and patients describe it as looking tired.
Eyelid ptosis follows diffusion toward the levator, and is a different and more distressing problem. It is rare, it resolves, and the risk is reduced by conservative placement, avoiding pressure and massage after treatment, and respecting the distance from the orbital rim that structured training teaches [2].
Both should be named in the consent conversation. A patient warned about heaviness experiences it as a known possibility; a patient not warned experiences it as negligence.
Who should not be treated
Botulinum toxin is a prescription-only medicine, and the decision to use it carries the contraindications of a drug rather than the cautions of a cosmetic. Disorders of the neuromuscular junction — myasthenia gravis, Lambert–Eaton syndrome, motor neurone disease — are contraindications, and their early presentations can be subtle enough that a new ptosis or a swallowing complaint deserves a diagnosis before it is treated. Medicines affecting neuromuscular transmission, aminoglycoside antibiotics among them, potentiate the effect. Treatment is avoided in pregnancy and breastfeeding, and postponed where there is infection at the intended site.
European product information for every licensed toxin carries a warning about effects spreading beyond the treatment site. Difficulty swallowing or breathing after treatment is an emergency, not a side effect to review at two weeks. None of this argues for hesitancy in appropriate patients; all of it belongs in the consultation and in the notes.
Principles that hold across products
- Treat the pattern of movement you observed, not the pattern in a diagram.
- Start conservatively and review. Adding at two weeks is easy; waiting out an over-treated forehead is not.
- Consider the whole upper face together, even when the patient asked about one line.
- Photograph in animation as well as at rest, so the review conversation has evidence.
- Products are not interchangeable unit for unit; the specifics belong to the product's own guidance and to your protocol, not to a general article.
Why this region teaches the rest
Everything that matters later — assessing dynamically, treating a system rather than a symptom, promising less than you expect to deliver, reviewing before adding — can be learned here at low cost. Injectors who rush through the upper face to reach fillers tend to arrive in the riskier regions without those habits, and that is where the habits are no longer optional.